Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 4Terminated 3Recruiting 3Completed 3Unknown 2Withdrawn 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Carcinoma, Non-Small-Cell Lung 387Breast Neoplasms 368Colorectal Neoplasms 242Stomach Neoplasms 222Carcinoma, Hepatocellular 155Lung Neoplasms 125Neoplasms 122Pancreatic Neoplasms 112Prostatic Neoplasms 101Rectal Neoplasms 98Neoplasm Metastasis 98Recurrence 94Ovarian Neoplasms 92Nasopharyngeal Carcinoma 89Esophageal Neoplasms 84Esophageal Squamous Cell Carcinoma 83Lymphoma, Large B-Cell, Diffuse 80Melanoma 78Lymphoma 72Small Cell Lung Carcinoma 71Sarcoma 71Leukemia, Myeloid, Acute 71Uterine Cervical Neoplasms 70Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 67Head and Neck Neoplasms 67Carcinoma, Renal Cell 65Triple Negative Breast Neoplasms 63Colonic Neoplasms 55

Interventions

copper dotatate CU-64 1Irinotecan 1Fluorodeoxyglucose F18 1Etoposide 1Copper 1Cisplatin 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡